Evaluation and Modeling with the Therapeutic Effects Group
Members
Maîtresse de conférences - praticienne hospitalière
UCBL
Tel: 04 72 11 94 07
Maître de conférences - praticien hospitalier
UCBL
Tel: 33 04 72 32 34 87
Professeur des universités - médecin généraliste
UCBL
Tel: 04 78 74 18 18
Maîtresse de conférences
UCBL
Tel: 33 04 78 78 57 83
Professeure des universités - médecin généraliste
UCBL
Tel: 04 78 77 72 86
Professeur d'université - praticien hospitalier
UCBL
Tel: 04 72 44 81 42
Doctorante
HCL
Assistant hospitalier universitaire
UCBL
Doctorant
UCBL
Tel: 04 72 44 81 42
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 72 16 80 99
Doctorante
autre
Tel: 04 72 44 81 42
Praticien hospitalier
HCL
Tel: 04 72 44 81 42
Professeur d'université - praticien hospitalier émérite
UCBL
Professeur d'université - praticien hospitalier
UCBL
Tel: 04 27 85 77 32
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 78 86 33 01
Post-doc
UCBL
Maîtresse de conférences - praticienne hospitalière
UCBL
Maître de conférences - praticien hospitalier
UCBL
Tel: 04 72 11 94 20
Doctorante
UCBL
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 72 12 94 37
Post-doc
UCBL
Doctorante
UCBL
Tel: 04 72 44 81 42
EMET presentation
The EMET team brings together doctors, pharmacists and research professors specializing in the evaluation and use of drug and non-drug therapies, around a single project built on two axes:
- the evaluation of therapies in clinical trials or observational studies;
- the construction of explanatory and predictive models, to better understand and therefore predict the effect of therapies, simulate their impacts at the individual and population level, and improve the innovation paradigm.
The EMET team is therefore part of two major dynamics in therapy: analysis of the level of evidence and precision medicine.
The fields of application are cardiovascular and metabolic diseases, primary care medicine, rare pediatric diseases (including genetic and autoimmune diseases), oncology and infectious diseases.
EMET members implement approaches using different mathematical models: direct comparison and network meta-analysis, pharmacokinetic/pharmacodynamic analysis, Bayesian networks and machine learning.
Education
The EMET team is specially involved in the teaching of pharmacology and therapeutics and the modeling of the treatment effect through the coordination of the Masters 2 Clinical Evaluation (EC) and Pharmacology modeling and clinical trials (PHAME), Interpretation of Therapeutic Trials (IET), Training of investigators in clinical drug trials (FIEC) and Training of clinical research assistants and clinical study technicians (FARCTEC). Teacher-researchers are also involved in the first (pharmacology), second (pharmacology / therapeutics, pharmacy) and third cycles (general medicine, pediatrics, internal medicine) in health training courses.
Society involvement
The members of the EMET team through their work and their interactions with the other components of the LBBE, National societies, governmental (HAS) or international (EMA) agencies, and the Hospices Civils de Lyon, are invested in current societal issues: rationalization of the use of health product resources, research ethics, gender equality, rationality of approaches in analyzing the diversity of human populations.
Publications
Display of 181 to 210 publications on 613 in total
Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures
Vaccines . 9 ( 12 ) : 1462
Journal article
see the publicationPopulation Pharmacokinetics and Dosing Simulation of Vancomycin Administered by Continuous Injection in Critically Ill Patient
Antibiotics . 10 ( 10 ) : 1228
Journal article
see the publicationRifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion
PLoS Pathogens . 17 ( 6 ) : e1009643
Journal article
see the publicationAdapting French COVID-19 vaccination campaign duration to variant dissemination
: p. 24
Report
see the publicationAdherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs
Pediatric Nephrology . 36 ( 3 ) : 581-589
Journal article
see the publicationSingle-Dose Nirsevimab for Prevention of RSV in Preterm Infants
New England Journal of Medicine . 383 ( 5 ) : 415-425
Journal article
see the publicationRole of ultrasonography in the assessment of correct endotracheal tube placement in neonates
Acta Paediatrica . 109 ( 5 ) : 1057-1059
DOI: 10.1111/apa.15097
Journal article
see the publicationEarly trajectories of skin thickening are associated with severity and mortality in systemic sclerosis
Arthritis Research & Therapy . 22 ( 1 ) : 30
Journal article
see the publicationFrench recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)
Orphanet Journal of Rare Diseases . 15 ( S2 ) : 351
Journal article
see the publicationAttention and Executive Disorders in Neurofibromatosis 1: Comparison Between NF1 With ADHD Symptomatology (NF1 + ADHD) and ADHD Per Se
Journal of attention disorders . 24 ( 13 ) : 1807-1823
Journal article
see the publicationImpact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France on volume and cost of drug deliveries, assessed with administrative databases
Seminars in Arthritis and Rheumatism . 50 : 1307 - 1313
Journal article
see the publicationDynamical modeling of pro- and anti-inflammatory cytokines in the early stage of septic shock
In Silico Biology . 13 ( 3-4 ) : 101-121
DOI: 10.3233/ISB-200474
Journal article
see the publicationDrug prescription goals in primary care: a cross-sectional study
BMC Health Services Research . 20 ( 1 ) : 6
Journal article
see the publicationPrevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta‐Analysis
Arthritis Care & Research = Arthritis Care and Research . 72 ( 6 ) : 838-849
DOI: 10.1002/acr.23901
Journal article
see the publicationDosage de la tryptase : un guide d'utilisation pour le clinicien
La Revue de Médecine Interne . 41 : 748 - 755
Journal article
see the publicationL'acéruléoplasminémie héréditaire, une pathologie à ne pas méconnaître
La Revue de Médecine Interne . 41 : 769 - 775
Journal article
see the publicationRecurrent superficial vein thrombosis revealing relapsing polychondritis associated with myelodysplastic syndrome
Rheumatology . 59 ( 11 ) : 3581-3581
Journal article
see the publicationANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance
La Presse Médicale . 49 ( 3 ) : 104031
Journal article
see the publicationThe benefit–risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials
Rheumatology . 59 ( 9 ) : 2226-2236
Journal article
see the publicationRectal endometriosis: predictive MRI signs for segmental bowel resection
European Radiology . 31 ( 2 ) : 884-894
Journal article
see the publicationSevere infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis
Autoimmunity Reviews . 19 ( 5 ) : 102505
Journal article
see the publicationEarly trajectories of skin thickening are associated with severity and mortality in systemic sclerosis
Arthritis Research & Therapy . 22 ( 1 ) : 30
Journal article
see the publicationAnalysis of ncidence of hrombotic omplications in the resence of ompeting isks
Thrombosis Research . 191 : 152
Journal article
see the publicationOutpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections
Frontiers in Medicine . 7 : 585658
Journal article
see the publicationNonparametric Methods in Population Pharmacokinetics
Journal of Clinical Pharmacology . 62 ( 2 ) : 142-157
DOI: 10.1002/jcph.1650
Journal article
see the publicationDrug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction
Fundamental & Clinical Pharmacology . 35 ( 2 ) : 208-216
DOI: 10.1111/fcp.12601
Journal article
see the publicationAzithromycin for COVID-19: More Than Just an Antimicrobial?
Clinical Drug Investigation . 40 ( 8 ) : 683-686
Journal article
see the publicationIntra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children
Clinical Pharmacokinetics . 59 ( 8 ) : 1049-1061
Journal article
see the publicationA population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk
British Journal of Clinical Pharmacology . 86 ( 8 ) : 1642-1653
DOI: 10.1111/bcp.14278
Journal article
see the publicationAdverse events related to ibuprofen treatment for patent ductus arteriosus in premature neonates
Archives de Pédiatrie . 27 : 452 - 455
Journal article
see the publication
You also, comment on this article